LTR Pharma rises 58% on fast-acting erectile dysfunction nasal spray success, page-9

I’m speechless. That’s a 320% gain in one month. This company has operated flawlessly since IPO and continues to tick box after box on its way to FDA approval and commercialisation.

My optimistic view is that LTP will gain approval for SPONTAN either during or at the end of Q1 2025 (between Feb and April). Don’t be surprised if this time next year they announce US distribution. It’s all been laid out folks. We are armed with a highly experienced, ambitious board of directors and medical experts who are the best in their field. This announcement will no doubt catch the attention of the big players, who will be watching very very closely in the weeks and months to follow. This is all a game of chess, and LTR pharma are only months away from checkmating the entire ED industry.